Key Events This Week
May 5: Profit wipeout amid tax anomaly raises red flags
May 6: Flat quarterly performance reported with mixed financial trends
May 8: Week closes at Rs.171.15, down 9.61%

Nath Bio-Genes Reports Flat Quarterly Performance Amid Mixed Financial Trends
2026-05-06 11:00:16Nath Bio-Genes (India) Ltd has reported a flat financial performance for the quarter ended March 2026, signalling a stabilisation after a period of decline. While net sales have shown robust growth, profitability metrics and earnings per share continue to face headwinds, reflecting a complex financial landscape for this micro-cap player in the Other Agricultural Products sector.
Read full news articleAre Nath Bio-Genes (India) Ltd latest results good or bad?
2026-05-05 19:16:48Nath Bio-Genes (India) Ltd reported its financial results for Q4 FY26, revealing a complex operational landscape. The company experienced a net profit of -₹0.01 crores, reflecting a significant decline of 100.68% year-on-year. This loss was primarily driven by an unusually high effective tax rate of 100.40%, which exceeded the pre-tax profit of ₹2.49 crores, effectively nullifying earnings for the quarter. In terms of revenue, Nath Bio-Genes recorded net sales of ₹51.59 crores, which represents a slight decline of 0.73% compared to the same quarter last year. However, this figure marked a more pronounced quarter-on-quarter decrease of 21.79% from ₹65.96 crores in Q3 FY26, indicating volatility in sales performance. The operating margin improved to 8.68%, a notable increase from 0.79% in Q4 FY25, suggesting some operational efficiency gains despite the overall profit loss. The company’s financial performa...
Read full news article
Nath Bio-Genes Q4 FY26: Profit Wipeout Amid Tax Anomaly Raises Red Flags
2026-05-05 09:49:12Nath Bio-Genes (India) Ltd., a micro-cap agricultural products company with a market capitalisation of ₹330.86 crores, reported a shocking loss of ₹0.01 crores for Q4 FY26, marking a complete reversal from the ₹0.94 crores profit posted in Q4 FY25. The stock plunged 7.87% on May 5, 2026, closing at ₹174.45, as investors reacted to an extraordinary tax charge that exceeded the company's pre-tax profit—a rare accounting anomaly that signals potential earnings quality concerns.
Read full news article
Nath Bio-Genes (India) Ltd is Rated Sell
2026-04-30 10:10:38Nath Bio-Genes (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 April 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article









